erlotinib has been researched along with Benign Neoplasms in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (8.00) | 29.6817 |
| 2010's | 18 (72.00) | 24.3611 |
| 2020's | 5 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Archibald, H; Dowell, L; Drew, L; Erlander, MG; Gray, NS; Greninger, P; Haber, DA; Hanke, JH; Iafrate, AJ; Lamb, J; Lee, D; Ma, XJ; Maheswaran, S; McDermott, U; Montagut, C; Njauw, CN; Raudales, R; Rothenberg, SM; Settleman, J; Sharma, SV; Sordella, R; Supko, JG; Tam, A; Tsao, H; Ulkus, LE | 1 |
| Bikker, JA; Brooijmans, N; Mansour, TS; Wissner, A | 1 |
| Chen, J; Li, HQ; Liu, PG; Lv, PC; Mao, WJ; Wang, KR; Xiong, J; Yang, Y; Zhou, CF; Zhu, HL | 1 |
| Li, HQ; Shi, L; Yan, T; Yang, Y; Zhou, CF; Zhu, HL | 1 |
| Bao, R; Cai, X; Forrester, J; Lai, CJ; Qian, C; Qu, H; Wang, J; Yin, L; Zhai, HX | 1 |
| Li, HQ; Lv, PC; Sun, J; Zhou, Y; Zhu, HL | 1 |
| Bell, RL; Bouska, J; Davidsen, SK; Hu, X; Hubbard, RD; Johnson, EF; Kovar, P; Mantei, RA; Osterling, DJ; Sheppard, GS; Tucker, L; Wang, GT; Wang, J; Wilsbacher, JL; Zhang, Q | 1 |
| Aertgeerts, K; Habuka, N; Hirokawa, A; Ishikawa, T; Iwamoto, K; Jennings, A; Miki, H; Ohta, Y; Sang, BC; Skene, R; Snell, G; Sogabe, S; Tanaka, T; Yano, J; Zou, H | 1 |
| Hou, YP; Li, DD; Liu, K; Lv, PC; Ye, YH; Zhang, H; Zhang, HJ; Zhu, HL | 1 |
| Dubey, PK; Pal, M; Piedrafita, FJ; Rajitha, C; Sunku, V; Veeramaneni, VR | 1 |
| Luo, Y; Qiu, KM; Wang, HH; Wang, LM; Wang, XM; Yang, XH; Zhu, HL | 1 |
| Chen, LW; Duan, YT; Tang, DJ; Tao, XX; Wang, PF; Xu, C; Yang, MR; Zhu, HL | 1 |
| Abouzid, KAM; Lasheen, DS; Milik, SN; Serya, RAT | 1 |
| Abbas, SY; Ammar, YA; Belal, A; Mehany, ABM; Mohamed, YA; Ragab, A; Sh El-Sharief, AM | 1 |
| Dang Thi, TA; Dinh, TV; Hoang Thi, P; Le Duc, T; Le Thi, TA; Le-Nhat-Thuy, G; Nguyen Quang, H; Nguyen Thanh, P; Nguyen Thi, N; Nguyen, HT; Nguyen, TV; Pham-The, H | 1 |
| Mathias, F; Montana, M; Terme, T; Vanelle, P | 1 |
| Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q | 1 |
| Abbas Bukhari, SN; Abdel-Aziz, M; Abdelbaset, MS; Abdelrahman, MH; Abuo-Rahma, GEA; Ali, TFS; Ramadan, M | 1 |
| Das, D; Hong, J | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Duan, G; Liu, T; Wan, Y; Xia, C; Xiao, Y | 1 |
| Chen, J; Kuang, P; Peng, X; Sun, Z | 1 |
| Chen, XB; Wang, S; Wang, SQ; Yu, B; Yuan, XH; Zhao, W | 1 |
| Ayati, A; Foroumadi, A; Moghimi, S; Toolabi, M | 1 |
| Cai, Z; Ghaleb, H; Huang, W; Jiang, Y; Liu, Y; Qian, H; Qiu, Q; Shi, W; Yin, Z; Zhang, P; Zhou, J; Zou, F | 1 |
9 review(s) available for erlotinib and Benign Neoplasms
| Article | Year |
|---|---|
How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.
Topics: Animals; Antineoplastic Agents; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Gene Amplification; Humans; Models, Molecular; Neoplasms; Point Mutation; Protein Domains; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2017 |
Antitumoral activity of quinoxaline derivatives: A systematic review.
Topics: Antineoplastic Agents; Humans; Neoplasms; Quinoxalines | 2019 |
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines | 2019 |
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2019 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.
Topics: Antineoplastic Agents; DNA Damage; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Neoplasms; Protein Kinases; Proteins; Structure-Activity Relationship; Topoisomerase Inhibitors | 2020 |
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Molecular Structure; Neoplasms | 2020 |
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Molecular Structure; Neoplasms; Pyrimidines; United States; United States Food and Drug Administration | 2021 |
Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy.
Topics: Antineoplastic Agents; ErbB Receptors; Humans; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Pyrimidines | 2021 |
16 other study(ies) available for erlotinib and Benign Neoplasms
| Article | Year |
|---|---|
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genotype; Humans; Neoplasms; Protein Kinase Inhibitors | 2007 |
Kinase domain mutations in cancer: implications for small molecule drug design strategies.
Topics: Amino Acid Sequence; Antineoplastic Agents; Drug Design; Enzyme Inhibitors; Humans; Molecular Sequence Data; Mutation; Neoplasms; Phosphotransferases; Protein Conformation | 2009 |
Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Models, Molecular; Neoplasms; Protein Binding; Protein Kinase Inhibitors; Receptor, ErbB-2; Structure-Activity Relationship; Thiazolidines | 2010 |
Synthesis and structure-activity relationships of N-benzyl-N-(X-2-hydroxybenzyl)-N'-phenylureas and thioureas as antitumor agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Models, Molecular; Neoplasms; Phenylurea Compounds; Protein Binding; Protein Conformation; Receptor, ErbB-2; Structure-Activity Relationship; Thiourea | 2010 |
Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Growth Processes; Enzyme Inhibitors; ErbB Receptors; Female; HeLa Cells; Hep G2 Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Mice, Nude; Neoplasms; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2010 |
Synthesis and biological evaluation of pyrazole derivatives containing thiourea skeleton as anticancer agents.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Computer Simulation; ErbB Receptors; Humans; Neoplasms; Pyrazoles; Thioamides; Thiourea | 2010 |
Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Mice; Mice, Inbred C57BL; Neoplasms; Rats; Receptor, ErbB-2; Receptor, IGF Type 1; Structure-Activity Relationship | 2010 |
Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.
Topics: Allosteric Regulation; Antineoplastic Agents; Crystallography, X-Ray; Drug Design; Enzyme Activation; ErbB Receptors; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Structure, Tertiary; Receptor, ErbB-2; Receptor, ErbB-4; Structure-Activity Relationship | 2011 |
The combination of 4-anilinoquinazoline and cinnamic acid: a novel mode of binding to the epidermal growth factor receptor tyrosine kinase.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cinnamates; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Models, Molecular; Molecular Targeted Therapy; Neoplasms; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2011 |
Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.
Topics: Antineoplastic Agents; Benzene Derivatives; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Neoplasms; Oxazines; Structure-Activity Relationship | 2011 |
Design, synthesis and biological evaluation of pyrazolyl-thiazolinone derivatives as potential EGFR and HER-2 kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2012 |
Design, synthesis and biological evaluation of pyrazolyl-nitroimidazole derivatives as potential EGFR/HER-2 kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; ErbB Receptors; Humans; Molecular Docking Simulation; Neoplasms; Nitroimidazoles; Protein Kinase Inhibitors; Pyrazoles; Receptor, ErbB-2 | 2016 |
Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Isatin; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors | 2018 |
Design, synthesis and evaluation of novel hybrids between 4-anilinoquinazolines and substituted triazoles as potent cytotoxic agents.
Topics: Amino Acid Sequence; Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Molecular Docking Simulation; Neoplasms; Quinazolines; Sequence Alignment; Structure-Activity Relationship; Triazoles | 2018 |
Discovery of novel thienoquinoline-2-carboxamide chalcone derivatives as antiproliferative EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chalcones; Drug Design; ErbB Receptors; Humans; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Quinolines | 2019 |
Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel | 2022 |